When is a fully covered self‑expanding metal stent (SEMS) preferred over an uncovered self‑expanding metal stent for malignant biliary obstruction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Fully Covered SEMS Should Be Preferred for Malignant Distal Biliary Obstruction

For malignant distal biliary obstruction, fully covered self-expanding metal stents (FCSEMSs) should be preferred over uncovered SEMS (UCSEMSs) due to significantly longer stent patency, lower rates of stent occlusion, and reduced need for reintervention, despite a higher migration risk that is clinically manageable.

Guideline Framework

The most recent EASL 2025 guidelines establish that self-expanding metal stents are the preferred modality for drainage in advanced distal cholangiocarcinoma, with superior therapeutic success rates and lower complication rates compared to plastic stents 1. While these guidelines specifically recommend uncovered SEMS for proximal cholangiocarcinoma (perihilar disease), they do not make definitive distinctions between covered and uncovered stents for distal malignant biliary obstruction, leaving this decision to be informed by research evidence.

Evidence Supporting Fully Covered SEMS

Stent Patency and Occlusion Rates

The most compelling recent evidence comes from multiple high-quality studies demonstrating clear advantages for FCSEMSs:

  • A 2023 large retrospective cohort (n=454) showed UCSEMSs had significantly higher stent occlusion rates (26.9% vs 8.9%, p<0.001) and shorter median time to occlusion (4.4 months vs 10.7 months, p=0.002) 2. This translated to higher rates of adverse events (33.5% vs 21.1%, p=0.023) and unplanned endoscopic reintervention (27.0% vs 11.1%, p=0.002).

  • A 2025 retrospective study (n=310) confirmed longer mean stent patency with FCSEMSs (445 vs 348 days, p=0.020), with multivariate analysis identifying UCSEMS as an independent risk factor for stent occlusion (HR=2.277, p<0.001) 3.

  • A 2026 Japanese multicenter study demonstrated lower recurrent biliary obstruction rates with covered laser-cut SEMS (20% vs 37%, p=0.034), particularly due to reduced stent occlusion (14% vs 37%, p=0.005) 4.

Mechanism of Benefit

The superiority of FCSEMSs stems from prevention of tumor ingrowth, which is the primary cause of UCSEMS failure. A 2013 randomized multicenter trial (n=120) showed tumor ingrowth occurred in 0% of covered SEMS versus 25% of uncovered SEMS (p<0.01), resulting in significantly longer patient survival time without stent dysfunction (187 vs 132 days, p=0.043) 5.

The Migration Trade-off

Migration Risk is Real but Manageable

FCSEMSs do carry a significantly higher migration risk:

  • 7.8% vs 1.1% in the 2023 cohort study 2
  • Migration was the primary concern in multiple studies 6

However, this increased migration risk does not translate into worse clinical outcomes because:

  1. Migration events are typically manageable with repeat intervention
  2. The overall adverse event rate remains lower with FCSEMSs due to the dominant benefit of preventing occlusion
  3. Modern covered stents with anti-migration features (uncovered flared ends, lower axial force) have minimized this complication 5

No Increased Risk of Cholecystitis or Pancreatitis

Contrary to theoretical concerns, recent evidence shows:

  • Similar rates of cholecystitis (0.3% vs 1.1%, p=0.872) and post-ERCP pancreatitis (6.3% vs 6.6%, p=0.90) between covered and uncovered stents 2
  • One 2026 study of multihole partially covered SEMS showed no cases of cholecystitis in the covered group 7

Survival and Quality of Life Considerations

While overall survival is similar between covered and uncovered SEMS (driven by underlying malignancy), the critical quality-of-life advantage lies in reduced reintervention rates:

  • Fewer unplanned endoscopic procedures (11.1% vs 27.0%) 2
  • Longer stent reintervention-free survival 2
  • Extended time before requiring repeat procedures (median 201 days to recurrent obstruction in successful cases) 8

For patients with limited life expectancy (typically <1 year with unresectable malignancy), avoiding repeat ERCPs and hospitalizations for stent occlusion represents a meaningful quality-of-life benefit.

Clinical Algorithm for Stent Selection

Choose Fully Covered SEMS when:

  • Distal malignant biliary obstruction (pancreatic cancer, distal cholangiocarcinoma)
  • Life expectancy >3 months (per ESMO guidelines) 9
  • Goal is palliation with minimal reintervention

Consider Uncovered SEMS when:

  • Perihilar/proximal cholangiocarcinoma (Bismuth III-IV) where covered stents may occlude side branches 1
  • Concern for cystic duct occlusion in specific anatomic situations (though evidence shows this is not a significant clinical problem)

Management of Stent Dysfunction

When FCSEMSs do fail, stent exchange (removal and replacement) is superior to stent-in-stent placement. A 2026 multicenter study showed SEMS stent exchange provided better secondary stent patency (161 days) compared to stent-in-stent with SEMS (104 days, HR=6.53, p=0.003) 10. The removability of FCSEMSs is therefore an additional advantage, with 100% successful removal rates reported 4.

Common Pitfalls to Avoid

  1. Don't use plastic stents for coaxial placement in occluded UCSEMSs - when UCSEMSs occlude, coaxial plastic stents have higher reocclusion rates (46.7%) compared to coaxial SEMS placement (19.7%, p=0.007) 2

  2. Don't assume migration risk outweighs occlusion risk - the data consistently shows net clinical benefit favors FCSEMSs despite migration

  3. Don't extrapolate proximal disease recommendations to distal disease - uncovered SEMS may be preferred for perihilar disease but this does not apply to distal obstruction 1

  4. Ensure adequate expertise - if ERCP fails, EUS-guided biliary drainage should be preferred over percutaneous drainage when experienced endoscopists are available 1

References

Related Questions

In an adult patient with unresectable malignant biliary obstruction, what are the risks and benefits of fully covered self‑expandable metal stents versus uncovered self‑expandable metal stents versus plastic biliary stents?
In a patient scheduled for a Whipple pancreaticoduodenectomy with markedly elevated bilirubin and surgery delayed >1 week, should a fully covered self‑expanding metal stent (SEMS) or an uncovered self‑expanding metal stent be used for biliary drainage?
Can cetirizine, montelukast, and bilastine be used together?
What are the key interview questions for a 59-year-old female presenting for follow-up after an emergency department visit for cardiac palpitations?
What is the appropriate initial management for a patient with spinal trauma?
What is the appropriate evaluation and management for pustular lesions on the hand?
What is the recommended evaluation and management for a pustular lesion on the little finger?
Can a patient with diarrhea‑predominant irritable bowel syndrome safely consume coconut milk?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.